Versant Capital Management, Inc Travere Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 562 shares of TVTX stock, worth $9,503. This represents 0.0% of its overall portfolio holdings.
Number of Shares
562
Previous 590
4.75%
Holding current value
$9,503
Previous $11,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$150 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$129 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$127 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$84.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$81.1 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.09B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...